Transcriptional expression of SLC16A7 as a biomarker of occult lymph node metastases in patients with head and neck squamous cell carcinoma
European Archives of Oto-Rhino-Laryngology · 2024
DOI: 10.1007/s00405-024-08882-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2024. Verfasst von Mercedes Camacho und 6 weiteren Autor:innen. Beteiligte Einrichtung: Genomics of Complex Diseases. Institut de Recerca, IIB Sant Pau, Barcelona, Spain. Hauptthemen laut MEDLINE: Lymphatic Metastasis, Head and Neck Neoplasms, Biomarkers, Tumor, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Fundación Científica Asociación Española Contra el Cáncer.
Abstract (Originalsprache)
PURPOSE: Glucose is the main energy substrate of tumor cells. This study aims to assess whether the transcriptional expression of glucose metabolism-related genes is associated with occult lymph node metastases in head and neck squamous cell carcinoma (HNSCC) patients. METHODS: We examined the transcriptional expression of a panel of glucose metabolism-related genes in a cohort of 53 patients with HNSCC without cervical lymph node involvement at the time of diagnosis (cN0) and subsequently treated with elective neck dissection. RESULTS: Occult lymph node metastases were found in 37.7% (n = 20) of the patients. Among the analyzed genes, SLC16A7 exhibited the strongest association with the presence of occult lymph node metastases. Patients with occult lymph node metastases (cN0/pN +) had significantly lower SLC16A7 expression values (p = 0.001). Patients with low SLC16A7 expression (n = 17, 32.1%) had a frequency of occult lymph node metastases of 76.5%, while for patients with high SLCA16A7 expression (n = 36, 67.9%) it was 19.4% (P = 0.0001). A multivariable analysis showed that patients with low expression of SLC16A7 had a 12.6 times higher risk of developing occult lymph node metastases. CONCLUSION: cN0 HNSCC patients with low SLC16A7 expression had a higher risk of occult lymph node metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genomics of Complex Diseases. Institut de Recerca, IIB Sant Pau, Barcelona, Spain.
- Otorhinolaryngology Head-Neck Surgery Department, Hospital de La Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. cvazquezl@santpau.cat.
- Otorhinolaryngology Head-Neck Surgery Department, Hospital de La Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
- MoBioFood Research Group, Department of Biochemistry and Biotechnology, Universitat Rovira I Virgili, Tarragona, Spain.
- Otorhinolaryngology Head-Neck Surgery Department. Hospital Clínic de Barcelona. IDIBAPS Universitat de Barcelona, Barcelona, Spain.
- Center On Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.
Förderung
- Instituto de Salud Carlos III
- Fundación Científica Asociación Española Contra el Cáncer
Zitieren
APA
Camacho, M., Vázquez-López, C., Valero, C., Holgado, A., Terra, X., Avilés-Jurado, F. X., & León, X. (2024). Transcriptional expression of SLC16A7 as a biomarker of occult lymph node metastases in patients with head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-024-08882-9
Vancouver
Camacho M, Vázquez-López C, Valero C, Holgado A, Terra X, Avilés-Jurado FX, et al. Transcriptional expression of SLC16A7 as a biomarker of occult lymph node metastases in patients with head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology. 2024. doi:10.1007/s00405-024-08882-9
BibTeX
@article{Camacho2024,
author = {Camacho, Mercedes and Vázquez-López, Cristina and Valero, Cristina and Holgado, Anna and Terra, Ximena and Avilés-Jurado, Francesc Xavier and León, Xavier},
title = {Transcriptional expression of SLC16A7 as a biomarker of occult lymph node metastases in patients with head and neck squamous cell carcinoma},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2024},
doi = {10.1007/s00405-024-08882-9}
}
EUVIMED